Mitchell C. Posner to Oncolytic Virotherapy
This is a "connection" page, showing publications Mitchell C. Posner has written about Oncolytic Virotherapy.
Connection Strength
0.221
-
Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application. Future Oncol. 2007 Oct; 3(5):545-56.
Score: 0.077
-
Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res. 2007 Sep 01; 67(17):8301-6.
Score: 0.076
-
Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol. 2006 Feb; 80(3):1110-20.
Score: 0.068